|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
93,700,000 |
Market
Cap: |
26.82(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.2833 - $0.71 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Fortress Biotech is a biopharmaceutical company focused on acquiring, developing and commercializing pharmaceutical and biotechnology products and product candidates. Through its partner company, Co. markets dermatology products including Qbrexza®, which is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane® (isotretinoin) capsule, which is an oral retinoid indicated for the treatment of severe recalcitrant nodular acne; as well as Ximino® (minocycline hydrochloride) extended release capsule, which is a tetracycline-class drug indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
10,000 |
60,000 |
1,894,573 |
6,056,667 |
Total Buy Value |
$17,589 |
$136,359 |
$3,290,364 |
$6,733,423 |
Total People Bought |
1 |
1 |
2 |
6 |
Total Buy Transactions |
1 |
2 |
7 |
17 |
Total Shares Sold |
10,000 |
10,000 |
10,000 |
10,000 |
Total Sell Value |
$18,900 |
$18,900 |
$18,900 |
$18,900 |
Total People Sold |
1 |
1 |
1 |
1 |
Total Sell Transactions |
1 |
1 |
1 |
1 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Klein Dov |
Director |
|
2024-05-20 |
4 |
S |
$1.89 |
$18,900 |
D/D |
(10,000) |
53,400 |
|
- |
|
Rosenwald Lindsay A Md |
President, CEO & Chairman |
|
2024-05-16 |
4 |
B |
$1.76 |
$17,589 |
D/D |
10,000 |
2,873,905 |
3.15 |
- |
|
Jin David |
Chief Financial Officer |
|
2024-04-01 |
4 |
A |
$1.70 |
$3,998 |
D/D |
2,352 |
238,268 |
|
- |
|
Rosenwald Lindsay A Md |
President, CEO & Chairman |
|
2024-01-05 |
4 |
B |
$2.38 |
$118,770 |
D/D |
50,000 |
2,863,905 |
3.23 |
- |
|
Rosenwald Lindsay A Md |
President, CEO & Chairman |
|
2024-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
216,465 |
2,813,905 |
|
- |
|
Weiss Michael S |
See Remarks |
|
2024-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
216,465 |
1,346,985 |
|
- |
|
Lorenz Kevin |
Director |
|
2024-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,333 |
24,304 |
|
- |
|
Rowinsky Eric K |
Director |
|
2024-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,666 |
68,797 |
|
- |
|
Klein Dov |
Director |
|
2024-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,666 |
63,400 |
|
- |
|
Harvey Jimmie |
Director |
|
2024-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,666 |
69,999 |
|
- |
|
Lobell J Jay |
Director |
|
2024-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,666 |
115,692 |
|
- |
|
Lu Lucy |
Director |
|
2024-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,333 |
11,890 |
|
- |
|
Hoenlein Malcolm |
Director |
|
2024-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,333 |
39,042 |
|
- |
|
Jin David |
Chief Financial Officer |
|
2023-12-20 |
4 |
A |
$0.00 |
$0 |
D/D |
140,000 |
235,916 |
|
- |
|
Weiss Michael S |
See Remarks |
|
2023-11-14 |
4 |
B |
$1.70 |
$249,999 |
D/D |
147,058 |
1,130,520 |
2.81 |
- |
|
Rosenwald Lindsay A Md |
President, CEO & Chairman |
|
2023-11-14 |
4 |
B |
$1.70 |
$2,664,776 |
D/D |
1,567,515 |
2,597,440 |
3.23 |
- |
|
Rosenwald Lindsay A Md |
President, CEO & Chairman |
|
2023-09-26 |
4 |
B |
$0.28 |
$28,330 |
D/D |
100,000 |
15,449,091 |
3.23 |
1% |
|
Rosenwald Lindsay A Md |
President, CEO & Chairman |
|
2023-08-18 |
4 |
B |
$9.34 |
$93,400 |
D/D |
10,000 |
112,500 |
3.23 |
-34% |
|
Rosenwald Lindsay A Md |
President, CEO & Chairman |
|
2023-08-17 |
4 |
B |
$11.75 |
$117,500 |
D/D |
10,000 |
102,500 |
3.23 |
-29% |
|
Jin David |
Chief Financial Officer |
|
2023-02-10 |
4 |
B |
$0.84 |
$30,000 |
D/D |
35,928 |
1,438,757 |
2.74 |
-17% |
|
Lobell J Jay |
Director |
|
2023-02-10 |
4 |
B |
$0.84 |
$250,000 |
D/D |
299,401 |
1,635,401 |
2.39 |
-17% |
|
Weiss Michael S |
See Remarks |
|
2023-02-10 |
4 |
B |
$0.84 |
$999,999 |
D/D |
1,197,604 |
14,752,034 |
3.23 |
-17% |
|
Lu Lucy |
Director |
|
2023-02-10 |
4 |
B |
$0.84 |
$10,000 |
D/D |
11,976 |
133,379 |
2.39 |
-17% |
|
Rowinsky Eric K |
Director |
|
2023-02-10 |
4 |
B |
$0.84 |
$10,000 |
D/D |
11,976 |
931,976 |
2.39 |
-17% |
|
Rosenwald Lindsay A Md |
President, CEO & Chairman |
|
2023-02-10 |
4 |
B |
$0.84 |
$2,000,000 |
D/D |
2,395,209 |
15,349,091 |
3.23 |
-17% |
|
158 Records found
|
|
Page 1 of 7 |
|
|